Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study
Oesophagogastric (OG) cancer is a highly lethal disease requiring novel treatment options. c-MYC and/or HER-2 amplified oesophageal cancer models have demonstrated sensitivity to BTK inhibition with ibrutinib. We evaluated the safety and efficacy of ibrutinib in patients with c-MYC and/or HER2 ampli...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI AG
2022-03-01
|
| Serier: | Current Oncology |
| Fag: | |
| Online adgang: | https://www.mdpi.com/1718-7729/29/4/176 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
